Articoli

Ricercatore e docente universitario sul settore scientifico disciplinare BIO/14– Farmacologia, settore concorsuale 05/G1 – Farmacologia. Farmacologia Clinica e Farmacognosia. Presta servizio presso il Dipartimento di Scienze della Vita e Biotecnologie (SVeB) dell’Università di Ferrara.

Membro del Collegio dei Docenti del Dottorato di Ricerca in Farmacologia e Oncologia Molecolare.

È collaboratore del Sistema Nazionale di Allerta Precoce e Risposta Rapida per le Droghe del Dipartimento Politiche Antidroga (DPA) della Presidenza del Consiglio dei Ministri.

È collaboratore e referente per differenti associazioni nazionali per lo studio dell’impiego delle sostanze psicoattive in contesti criminogeni e settari.

Nel 2001 Dottorato di Ricerca in Farmacolgia Cellulare e Molecolare, Facoltà di Medicina, Dipartimento di Medicina Clinica e Sperimentale.

Dal 2005 è docente di “Tossicologia” presso l’Università di Ferrara.

Nel 2012 Diploma di Specializzazione in “Formazione Multisciplinare sulle Dipendenze” (decreto 290/2012 del Presidente della Scuola Superiore della Pubblica Amministrazione) presso la Scuola sulle Dipendenze del Dipartimento Politiche Antidroga, Presidenza del Consiglio dei Ministri.

Associazioni di Riferimento

Socio O.N.A.P. (Osservatorio Nazionale Abusi Psicologici)

Socio SIF (Società Italiana di Farmacologia)

Socio SINS (Società Italiana di Neuroscienze)

Socio GIPF (Gruppo Italiano di Patologia Forense)

Socio FENS (Federation of European Neuroscience Societies)

Socio SfN (Society for Neuroscience)

Socio ISCA (Italian Scientific Community on Addiction)

Socio ISA (Italian School on Addiction)

Socio ICSA (International Cultic Studies Association)

Pubblicazioni

1. Morari M., Sbrenna S., Marti M., Caliari F., Bianchi C. and Beani L. (1998) NMDA and non-NMDA ionotropic glutamate receptors modulate striatal acetylcholine release via pre- and postsynaptic mechanisms. J. Neurochem. 71, 2006-2017. (IF= 4,337; n° citazioni = 30)
2. Morari M., Marti M., Sbrenna S., Fuxe K., Bianchi C. and Beani L. (1998) Reciprocal dopamine-glutamate modulation of release in the basal ganglia. Neurochem. Int. 33, 383-397. (IF= 3,601; n° citazioni = 90)
3. Morari M., Sbrenna S., Marti M., O’Connor WT., Bianchi C., Fuxe K. and Beani L. (1998) Evidence for a striatal NMDA receptor modulation of the nigral glutamate release. A dual probe microdyalisis study in the awake freely moving rat. Eur. J. Neurosci. 10, 1716-1722. (IF= 3,658; n° citazioni = 17)
4. Marti M., Sbrenna S., Fuxe K., Bianchi C., Beani L. and Morari M. (1999) In vitro evidence for increased facilitation of striatal acetylcholine release via pre- and postsynaptic NMDA receptors in hemiparkinsonian rats. J. Neurochem. 72, 875-878. (IF= 4,337; n° citazioni = 14)
5.  Sbrenna S., Marti M., Morari M., Calò G., Guerrini R., Beani L. and Bianchi C. (1999) L-glutamate and gamma-aminobutyric acid efflux from rat cerebrocortical synaptosomes: modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors. J. Pharmacol. Exp. Ther. 291,1365-1371. (IF= 4,017; n° citazioni = 24)
6. Marti M., Bregola G., Morari M., Gemignani A. and Simonato M. (2000) Somatostatin release in the hippocampus in the kindling model of epilespy: a microdialysis study. J. Neurochem. 74, 2497-2503. (IF= 4,337; n° citazioni = 15)
7. Marti M., Sbrenna S., Fuxe K., Bianchi C., Beani L. and Morari M. (2000) Increased responsitivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson’s disease. A dual probe microdialysis study in hemiparkinsonian rats. Eur. J. Neurosci. 12, 1848-1850. (IF= 3,658; n° citazioni = 18)
8. Sbrenna S., Marti M., Morari M., Calò G., Guerrini R., Beani L. and Bianchi C. (2000) Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin. Br J. Pharmacol. 130, 425-433. (IF= 4,925; n° citazioni = 52)
9.  Marti M., Bregola G., Binaschi A., Gemignani A. and Simonato M. (2000) Kindling seizure-evoked somatostatin release in the hippocampus: inhibition by MK-801. Neuroreport 11, 3209-3212. (IF= 1,822; n° citazioni = 1)
10. Marti M., Paganini F., Stocchi S., Bianchi C., Beani L. and Morari M. (2001) Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release. Eur. J. Neurosci. 14, 1181-1184. (IF= 3,658; n° citazioni = 27)
11. Marti M., Guerrini R., Beani L., Bianchi C. and Morari M. (2002) Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat. Neuroscience 112, 153-160. (IF= 3,215; n° citazioni = 24)
12. Calò G., Rizzi A., Rizzi D., Bigoni R., Guerrini R., Marzola G., Marti M., McDonald J., Morari M., Lambert D.G., Salvatori S. and Regoli D. (2002) [Nphe¹, Arg¹⁴, Lys ¹⁵] nociceptin-NH₂, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br. J. Pharmacol. 136, 303-311. (IF= 4,925; n° citazioni = 107)
13. Pisani A., Bonsi P., Catania MV., Giuffrida R., Morari M., Marti M., Centonze D., Bernardi G., Kingston A.E. and Calabresi P. (2002) Metabotropic glutamate 2, mGlu2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurones. J. Neurosci. 22, 6176-6185. (IF= 7,271; n° citazioni = 39)
14. Siniscalchi A., Rodi D., Morari M., Marti M., Cavallini S., Marino S., Beani L. and Bianchi C. (2002) Direct and in direct inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro. Br. J. Pharmacol. 136, 1178-1184. (IF= 4,925; n° citazioni = 8)
15. Marti M., Mela F., Bianchi C., Beani L. and Morari M. (2002) Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo. Opposite role for D₁ and D₂ receptors. J. Neurochem. 83, 635-644. (IF= 4,337; n° citazioni = 39)
16. Marti M., Stocchi S., Paganini F., Mela F., De Risi C., Calò G., Guerrini R., Barnes T.A., Lambert D.G., Beani L., Bianchi C. and Morari M. (2003) Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. Br. J. Pharmacol. 38, 91-98. (IF= 4,925; n° citazioni = 34)
17. Marti M., Paganini F., Stocchi S., Mela F., Beani L., Bianchi C. and Morari M. (2003) Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group II metabotropic and NMDA receptors. J. Neurochem. 84, 792-802. (IF= 4,337; n° citazioni = 11)
18. Calabresi P., Marti M., Picconi B., Saulle E., Centonze D., Pisani F. and Bernardi G. (2003) Complementary mechanisms for the neuroprotective effects of lamotrigine and remacemide in striatal neurons. Exp Neurol 182, 461-469. (IF=4,436; n°citazioni=)
19. Marti M., Mela F., Ulazzi L., Hanau S., Stocchi S., Paganini F., Beani L., Bianchi C. and Morari M. (2003) Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease. Eur. J. Neurosci. 18, 759-767. (IF= 3,658; n° citazioni = 8)
20. Saulle E., Gubellini P., Picconi B., Centonze D., Tropepi D., Pisani A., Morari M., Marti M., Rossi L., Papa M., Bernardi G. and Calabresi P. (2004) Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington’s disease. Mol. Cell. Neurosi. 25, 9-20. (IF= 3,861; n° citazioni = 32)
21. Mela F., Marti M., Ulazzi L., Vaccari E., Zucchini S., Trapella C., Salvadori S., Beani L., Bianchi C. and Morari M. (2004) Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex. Eur. J. Neurosci. 19, 1317-1324. (IF= 3,658; n° citazioni = 25)
22. Marti M., Mela F., Veronesi C., Guerrini R., Salvadori S., Federici M., Mercuri N.B., Rizzi A., Franchi G., Beani L., Bianchi C. and Morari M. (2004) Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J. Neurosci. 24, 6659-6666. (IF= 7,271; n° citazioni = 52)
23. Marti M., Mela F., Guerrini R., Calò G., Bianchi C. and Morari M. (2004) Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J. Neurochem. 91, 1501-1504. (IF= 4,337; n° citazioni = 22)
24. Marti M., Manzalini M., Fantin  M., Bianchi C., Della Corte L. and Morari M. (2005) Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra and endogenous striatal substance P and dopamine. J. Neurochem. 93, 195-205. (IF= 4,337; n° citazioni = 11)
25. Cavallini S., Marti M., Marino S., Selvatici R., Beani L., Bianchi C. and Siniscalchi A. (2005) Effects of chemical ischemia in cerebral cortex slices. Focus on nitric oxide. Neurochem. Int. 47, 482-490. (IF= 3,601; n° citazioni = 8)
26. Marti M., Mela F., Fantin M., Zucchini S., Brown J.M. Witta J., Di Benedetto M., Buzas B., Reinscheid R.K., Salvadori S., Guerrini R., Romualdi P., Candeletti S., Simonato M., Cox B.M. and Morari M. (2005) Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson’s disease. J. Neurosci. 95, 9591-9601. (IF= 7,271; n° citazioni = 36)
27. Mela F., Marti M., Fiorentini C., Missale C. and Morari M. (2006) Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: role of P/Q-type high voltage activated Ca⁺⁺ channels and endogenous dopamine. Mol. Cell. Neurosci 31, 284-292. (IF= 3,861; n° citazioni = 6)
28. Mela F., Marti M., Dekundy A., Danysz W., Morari M. and Cenci M.A. (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson´s disease. J. Neurochem. 101, 483-497. (IF= 4,337; n° citazioni = 70)
29. Marti M., Trapella C., Viaro R. and Morari M. (2007) The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J. Neurosci. 27, 1297-1307. (IF= 7,271; n° citazioni = 28)
30. Fantin M., Marti M., Auberson Y.P. andMorari M. (2007) NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathways. J. Neurochem 103, 2200-2211. (IF= 4,337; n° citazioni = 12)
31. Esposito E., Fantin M., Marti M., Drechsler M., Paccamiccio L., Mariani P., Sivieri E., Menegatti E., Morari M. and Cortesi R. (2007) Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm. Res. 30, 430-438. (IF= 3,612; n° citazioni = 23)
32. Viaro R., Sanchez-Pernaute R., Marti M., Trapella C., Isacson O. and Morari M. (2008) Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol. Dis. 30, 340-348. (IF= 5,121; n° citazioni = 17)
33. Mabrouk O.S., Volta M., Marti M. and Morari M. (2008) Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats. New insights into the role of delta receptors in parkinsonism. J. Neurochem. 107, 1647-1659.(IF= 4,337; n° citazioni = 11)
34. Marti M., Trapella C. and Morari M. (2008) The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway. Positive interaction with L-DOPA. J. Neurochem. 107, 1683-1696. (IF= 4,337; n° citazioni = 13)
35. Marti M., Viaro R., Guerrini R., Franchi G. and Morari M. (2009) Nociceptin/orphanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata. Neuropsychopharmacology 34, 341-355. (IF= 6,685; n° citazioni = 8)
36. Mabrouk O.S., Marti M., Salvadori S. and Morari M. (2009) The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway. Neuroscience 164, 360-369. (IF= 3,215; n° citazioni = 4)
37. Mabrouk O.S., Marti M. and Morari M. (2010) Endogenous nociceptin/orphanin FQ contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice. Neuroscience 166, 40-48. (IF= 3,215; n° citazioni = 6)
38. Viaro R., Marti M. and Morari M. (2010) Dual motor response to L-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: paradoxical inhibition is relieved by D2/D3 receptor blockade. Exp. Neurol. 223, 473-484. (IF= 4,436; n° citazioni = 7)
39. Volta M., Marti M., McDonald J., Molinari S., Camarda V., Pelà M., Trapella C. and Morari M. (2010) Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-Cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4). Peptides 31, 1194-1204. (IF= 2,654; n° citazioni = 5)
40. Marti M., Sarubbo S., Latini F., Cavallo M., Eleopra R., Biguzzi S., Lettieri C., Conti C., Simonato M., Zucchini S., Quatrale R., Sensi M., Candeletti S., Romualdi P. and Morari M. (2010) Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson’s disease. Mov. Disord. 25, 1723-1732. (IF= 4,480; n° citazioni = 5)
41. Volta M., Mabrouk O.S., Bido S., Marti M. and Morari M. (2010) Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson’s disease: a behavioral and neurochemical study in reserpinized mice. J. Neurochem. 115, 1543-1555. (IF= 4,337; n° citazioni = 4)
42. Rizzi A., Molinari S., Marti M., Marzola G., Calo’ G. (2011) Nociceptin/orphanin FQ receptor knockout rats: in vitro and in vivo studies. Neuropharmacology 60, 572-579. (IF= 4,677; n° citazioni = 1)
43. Volta M., Viaro R., Trapella C., Marti M., Morari M. (2011) Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity. Exp. Neurol. 228,126-137. (IF= 4,436; n° citazioni = 2)
44. Bido S., Marti M. and Morari M. (2011) Amantadine attenuates levodopa-induced dyskinesias in mice and rats preventing accompanying rise in GABA nigral levels. J. Neurochem. 118,1043-1055. (IF= 4,337; n° citazioni = 0)
45. Mela F., Marti M., Bido S. and M. Angela Cenci M.A. (2012) In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiol. Dis.  45, 573-582. (IF= 5,121; n° citazioni = 0)
46. Costa C., Sgobio C., Siliquini S., Tozzi A., Cantucci M., Ghiglieri V., Di Filippo M., Pendolino V., de Iure A., Marti M., Morari M., Spillantini M.G., La Tagliata E.C., Pascucci T., Puglisi-Allegra S., Gardoni F., Di Luca M., Picconi B. and Calabresi P. (2012) Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson’s disease. Brain, 135, 1884-1899 (IF= 9,232; n° citazioni = 0)
47. Buzzi A., Chikhladze M., Falcicchia C., Paradiso B., Lanza G., Soukupova M., Marti M., Morari M., Franceschetti S., Simonato M. (2012) Loss of cortical GABA terminals in Unverricht-Lundborg disease. Neurobiol Dis. 47, 216-224. (IF= 5,121; n°citazioni = 0)
48. Marti M., Mela F., Budri M., Volta M., Malfacini D., Molinari S., Zaveri N.T., Ronzoni S., Petrillo P., Calò G., Morari M. (2012) Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111. Br. J. Pharmacol. doi: 10.1111/j.1476-5381.2012.02219.x. (IF= 4,925; n° citazioni = 0)
49. Marti M., Rodi D., Li Q., Guerrini R., Fasano S., Morella I., Tozzi A., Brambilla R., Calabresi P., Simonato M., Bezard E. and Morari M. (2012) Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias. J Neurosci 32: 16106-16119 (IF= 7,271; n° citazioni = 0)